Social media

How to navigate EU MAA Regulations and Registration Regulatory legislation in China differs substantially from that of the European Union. For Chinese biotech companies looking to enter this market it is critical to ass...

Latest issue out now. Keep up to date on the most recent regulatory changes in the world of pharma, biotech and medical device clinical trials with ICON’s Regulatory Intelligence Newsletter. Join thousands of subscribe...

We're pleased to share highlights of our ongoing CSR initiatives in Chennai. Colleagues from ICON's India team recently joined a Plantation Drive at SOS Children's Village, planting over 50 saplings as part of our ongoi...

On 30 March – 2 April at the World Vaccine Congress, speak with ICON experts at booth 222 to learn how our experience across 180+ vaccine studies, end‑to‑end product development expertise, and fully integrated vaccine‑de...

How is AI transforming vaccine‑trial execution? On 31 March at 11:40 am at the World Vaccine Congress, join our interactive working group session, “Vaccine trials: How AI shifts execution from static plans to living sys...

Rare autoimmune diseases can leave patients particularly vulnerable to infection, but they often require unique considerations for vaccination. Learn what makes these cases so unique, and what to take into account when b...

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil...

Join ICON’s Dr. Anne Behringer on 25 March at 03:00 for a virtual presentation on “Cross-Border Recruitment in Clinical Trials: A Perspective on Operational Reality”. Learn more https://ow.ly/o25L50Yr8W3

Attending #OCTSoutheast 10-11 March? Stop by booth \#37 to learn how we support biotechs with flexible clinical development, operational expertise and data‑driven decision‑making. https://lnkd.in/ehPmQF\_H

From feasibility to activation, study start-up delays can erode momentum and inflate costs. ICON’s Brian Mallon offers perspective and outlines practical fixes, including AI-driven contracting, early site engagement, and...

Formulations in early clinical development require a delicate balance of flexibility, simplicity, and scientific rigor. In first‑in‑human trials, dose ranges can vary by 10–100 fold increase between the starting dose a...

ICON has participated in 193 neurodegenerative and neuromuscular studies, enrolling 18,200+ patients at 4,800+ sites globally. Meet our experts at #ADPD2026, booth \#29 to learn how we can support your neurodegeneration ...